Lupin Gets USFDA Approval for Generic Seizure Medication
Lupin has received USFDA approval to market a generic version of Topiramate extended-release capsules for the treatment of seizures in patients aged 6 and older.
New Delhi, Jul 12 (PTI) Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic medication to treat seizures.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.
The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.
Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.
The company has received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules in the US, the drug firm said in a statement.
The product is a generic equivalent of Supernus Pharmaceuticals, Inc.'s Trokendi XR extended-release capsules, it added.
Topiramate extended-release capsules are indicated for the treatment of seizures in patients six years of age and older.
As per IQVIA MAT, Topiramate extended-release capsules had an estimated annual sale of USD 253 million in the US.
Shares of Lupin ended 1.04 per cent lower at Rs 1,798 apiece on the BSE.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.33 ( -3.81)
- 63645615
- Standard Capital
- 0.56 ( 0.00)
- 20453140
- Guj. Toolroom Lt
- 1.67 ( -2.91)
- 16188375
- G G Engineering
- 0.98 ( -1.01)
- 14086993
- YES Bank Ltd.
- 17.40 (+ 1.28)
- 13845365
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback